DaVita PE Ratio 2010-2025 | DVA
Current and historical p/e ratio for DaVita (DVA) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. DaVita PE ratio as of July 07, 2025 is 15.13.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| DaVita PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2025-07-07 |
142.81 |
|
14.15 |
| 2025-03-31 |
152.97 |
$10.09 |
15.16 |
| 2024-12-31 |
149.55 |
$10.74 |
13.92 |
| 2024-09-30 |
163.93 |
$9.27 |
17.68 |
| 2024-06-30 |
138.57 |
$9.39 |
14.76 |
| 2024-03-31 |
138.05 |
$8.80 |
15.69 |
| 2023-12-31 |
104.76 |
$7.40 |
14.16 |
| 2023-09-30 |
94.53 |
$6.52 |
14.50 |
| 2023-06-30 |
100.47 |
$5.03 |
19.97 |
| 2023-03-31 |
81.11 |
$5.42 |
14.96 |
| 2022-12-31 |
74.67 |
$5.78 |
12.92 |
| 2022-09-30 |
82.77 |
$6.83 |
12.12 |
| 2022-06-30 |
79.96 |
$8.06 |
9.92 |
| 2022-03-31 |
113.11 |
$8.40 |
13.47 |
| 2021-12-31 |
113.76 |
$8.88 |
12.81 |
| 2021-09-30 |
116.26 |
$8.59 |
13.53 |
| 2021-06-30 |
120.43 |
$7.51 |
16.04 |
| 2021-03-31 |
107.77 |
$6.49 |
16.61 |
| 2020-12-31 |
117.40 |
$6.29 |
18.66 |
| 2020-09-30 |
85.65 |
$6.67 |
12.84 |
| 2020-06-30 |
79.14 |
$6.34 |
12.48 |
| 2020-03-31 |
76.06 |
$6.36 |
11.96 |
| 2019-12-31 |
75.03 |
$5.37 |
13.97 |
| 2019-09-30 |
57.07 |
$2.59 |
22.03 |
| 2019-06-30 |
56.26 |
$0.82 |
68.61 |
| 2019-03-31 |
54.29 |
$0.71 |
76.46 |
| 2018-12-31 |
51.46 |
$0.79 |
65.14 |
| 2018-09-30 |
71.63 |
$3.33 |
21.51 |
| 2018-06-30 |
69.44 |
$3.01 |
23.07 |
| 2018-03-31 |
65.94 |
$2.13 |
30.96 |
| 2017-12-31 |
72.25 |
$3.44 |
21.00 |
| 2017-09-30 |
59.39 |
$2.60 |
22.84 |
| 2017-06-30 |
64.76 |
$6.50 |
9.96 |
| 2017-03-31 |
67.97 |
$6.11 |
11.12 |
| 2016-12-31 |
64.20 |
$4.29 |
14.97 |
| 2016-09-30 |
66.07 |
$3.46 |
19.10 |
| 2016-06-30 |
77.32 |
$1.70 |
45.48 |
| 2016-03-31 |
73.38 |
$2.22 |
33.05 |
| 2015-12-31 |
69.71 |
$1.23 |
56.67 |
| 2015-09-30 |
72.33 |
$2.22 |
32.58 |
| 2015-06-30 |
79.47 |
$2.07 |
38.39 |
| 2015-03-31 |
81.28 |
$1.97 |
41.26 |
| 2014-12-31 |
75.74 |
$3.34 |
22.68 |
| 2014-09-30 |
73.14 |
$3.37 |
21.70 |
| 2014-06-30 |
72.32 |
$3.16 |
22.89 |
| 2014-03-31 |
68.85 |
$3.67 |
18.79 |
| 2013-12-31 |
63.37 |
$2.96 |
21.45 |
| 2013-09-30 |
56.90 |
$2.72 |
20.92 |
| 2013-06-30 |
60.40 |
$2.83 |
21.34 |
| 2013-03-31 |
59.30 |
$2.14 |
27.71 |
| 2012-12-31 |
55.27 |
$2.73 |
20.24 |
| 2012-09-30 |
51.81 |
$2.76 |
18.80 |
| 2012-06-30 |
49.11 |
$2.72 |
18.09 |
| 2012-03-31 |
45.09 |
$2.74 |
16.48 |
| 2011-12-31 |
37.91 |
$2.49 |
15.25 |
| 2011-09-30 |
31.34 |
$2.06 |
15.25 |
| 2011-06-30 |
43.31 |
$1.92 |
22.55 |
| 2011-03-31 |
42.76 |
$1.93 |
22.21 |
| 2010-12-31 |
34.75 |
$1.97 |
17.68 |
| 2010-09-30 |
34.52 |
$2.15 |
16.09 |
| 2010-06-30 |
31.22 |
$2.10 |
14.87 |
| 2010-03-31 |
31.70 |
$2.09 |
15.17 |
| 2009-12-31 |
29.37 |
$2.03 |
14.47 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$10.763B |
$12.816B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
